𝔖 Bobbio Scriptorium
✦   LIBER   ✦

MK-0457, an Aurora kinase and BCR–ABL inhibitor, is active in patients with BCR–ABL T315I leukemia

✍ Scribed by Giles, F J; Swords, R T; Nagler, A; Hochhaus, A; Ottmann, O G; Rizzieri, D A; Talpaz, M; Clark, J; Watson, P; Xiao, A; Zhao, B; Bergstrom, D; Le Coutre, P D; Freedman, S J; Cortes, J E

Book ID
115439261
Publisher
Nature Publishing Group
Year
2012
Tongue
English
Weight
221 KB
Volume
27
Category
Article
ISSN
0887-6924

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dynamic change of T315I BCR-ABL kinase d
Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors
✍ Wan-Seok Kim; Dongho Kim; Dong-Wook Kim; Il-Young Kweon; Soo-Hyun Kim; Hyun-Gyun 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 212 KB 👁 1 views

## Abstract We analysed the dynamic change of imatinib‐resistant mutations in BCR‐ABL kinase domain focusing on T315I mutation during dasatinib or nilotinib therapy. Fifty‐five imatinib‐resistant chronic myeloid leukaemia patients (32 patients with imatinib‐resistant mutations and 23 patients witho